Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC Form 4 December 21, 2007 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading SCHLEIFER LEONARD S Issuer Symbol REGENERON (Check all applicable) PHARMACEUTICALS INC [REGN] _X_ Director X__ 10% Owner Other (specify X_Officer (give title (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) Chief Exec Officer & President 777 OLD SAW MILL RIVER 12/20/2007 ROAD (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting TARRYTOWN, NY 10591 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of 6. Transaction(A) or Disposed of (D) Securities Ownership Indirect Security (Month/Day/Year) Execution Date, if (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Direct Beneficial anv (Month/Day/Year) (Instr. 8) Owned (D) or Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4) (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Common \$ 12/20/2007 $M^{(1)}$ 37.370 93,917 D А Stock 8.625 Common 12/20/2007 F⁽¹⁾ 14.466 D 79,451 D 22.28Stock Common 12/20/2007 **F**⁽¹⁾ 7,741 D D 71,710 22.28 Stock Common By 401(k) Ι 4,028 Stock Plan

1

By Son

900

I

2005

0.5

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	ate	7. Title and <i>L</i> Underlying S (Instr. 3 and	Securit
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo Num Shar
Non-Qualified Stock Options (right to buy)	\$ 8.625	12/20/2007		M <u>(1)</u>	37,370	(2)	01/01/2008	Common Stock	37
Class A Stock	<u>(3)</u>					(3)	<u>(3)</u>	Common Stock	1,7
Class A Stock	<u>(3)</u>					(3)	(3)	Common Stock	29

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
SCHLEIFER LEONAI 777 OLD SAW MILL TARRYTOWN, NY 10	RIVER ROAD	Х	Х	Chief Exec Officer & President			
Signatures							
/s/**Leonard S. Schleifer	12/20/20	07					
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- (2) This stock option was granted on January 1,1998 and became exercisable in five equal annual installments, commencing one year after the date of grant.
- (3) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. "font-family:inherit;font-size:10pt;">/s/ Joseph W. Mulpas

Joseph W. Mulpas

Vice President and Chief Accounting Officer

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

EXHIBIT INDEX

Exhibit	Description
Number	Description

99.1 Press Release, dated July 31, 2014, issued by NiSource Inc.